US Pharma MarketingOutlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin (bevacizumab) in the U.S., with the FDA now agreeing that the drug has demonstr After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources…
After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness.
Source: FiercePharma